X

JAMA Network

JAMA Network
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

This study aims to find if ivosidenib treatment improves overall survival outcomes vs placebo among patients with chemotherapy-refractory cholangiocarcinoma with IDH1 mutation. 

JAMA Network
09/23/2021
Association Between Measurable Residual Disease in Patients With Intermediate-Risk AML and First Remission, Treatment, and Outcomes

This study suggests that clinical decisions based on dynamic measurable residual disease might be associated with improved therapy stratification and optimized postremission treatment for patients

JAMA Network
07/07/2021
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel, marketed as Breyanzi, is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
03/16/2021
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
03/16/2021
Subscribe to JAMA Network

source list reference

rgb(171, 222, 222)
#7d60d9
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
#352625
#4d4537
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
#d2093c
#8e3f1c
rgb(242, 0, 137)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(80, 147, 199)
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
#89f67c
#49a21d
rgb (132, 101, 173)
#2c990a
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
#a60538
rgb(2, 230, 230)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834